Julien Grogg - MaxiVAX SA | 人才画像

基本信息

Career Trajectory

Bio

Leading product & technology development in the pharmaceutical industry, from lead optimization to market access. Biomedical engineer, with expertise in ATMPs & cell marcoencapsulation technologies. 15+ years demonstrating success in achieving complex deliverables in a highly regulated, cross-functional environment, with competing priorities. Co-inventor of 2 medical products harnessing cell encapsulation technologies; one accessed market, the other one is part of an ATMP currently in preclinical development. Science-driven, hands-on, and results-oriented.

Research Interests

Papers共 27 篇Author StatisticsCo-AuthorSimilar Experts

By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选

Table 1 from A First-in-Human Phase I Clinical Study with MVX-ONCO-1, a Personalized Active Immunotherapy, in Patients with Advanced Solid Tumors

Rémi Vernet,Eugenio Fernandez,Denis Migliorini, Virginie Ancrenaz,Emily Charrier,Marie-Claude Belkouch,Olivier Von Rohr,Muriel Urwyler,Claudio De Vito, Jessica Renaux,Jean Villard,Olivier Rubin,Julien Grogg,Nicolas Mach

crossref（2024）

Cited0Views0Bibtex

Figure 5 from A First-in-Human Phase I Clinical Study with MVX-ONCO-1, a Personalized Active Immunotherapy, in Patients with Advanced Solid Tumors

crossref（2024）

Cited0Views0Bibtex

59P Long Term Survival Data from All Recurrent/metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) Patients Treated with MVX-ONCO-1 During Open-Labelled Phase I and Phase IIa Clinical Trials

N. Mach, E. Fernandez, R. Vernet, M. Urwyler, O. von Rohr, E. Charrier, M-C. Belkouch, V. Saingier, F. Courtout, C. de Vito,V. Ancrenaz,N. Dulguerov,W. Karenovics,J. Grogg, J. Renaux, T. Brezina,T. Rordorf,M. Joerger,O.A. Michielin, J. Villard

Immuno-Oncology and Technology (2024): 100870

Cited0Views0Bibtex

Table 3 from A First-in-Human Phase I Clinical Study with MVX-ONCO-1, a Personalized Active Immunotherapy, in Patients with Advanced Solid Tumors

crossref（2024）

Cited0Views0Bibtex

Table 5 from A First-in-Human Phase I Clinical Study with MVX-ONCO-1, a Personalized Active Immunotherapy, in Patients with Advanced Solid Tumors

crossref（2024）

Cited0Views0Bibtex

A First-in-human Phase I Clinical Study with MVX-ONCO-1, a Personalized Active Immunotherapy, in Patients with Advanced Solid Tumors

Remi Vernet,Eugenio Fernandez,Denis Migliorini, Virginie Ancrenaz,Emily Charrier,Marie-Claude Belkouch,Olivier Von Rohr,Muriel Urwyler,Claudio De Vito, Jessica Renaux,Jean Villard,Olivier Rubin,Julien Grogg,Nicolas Mach

CANCER RESEARCH COMMUNICATIONSno. 8 (2024): 2089-2100

Cited0Views0WOSBibtex

Figure 2 from A First-in-Human Phase I Clinical Study with MVX-ONCO-1, a Personalized Active Immunotherapy, in Patients with Advanced Solid Tumors

crossref（2024）

Cited0Views0Bibtex

Table 4 from A First-in-Human Phase I Clinical Study with MVX-ONCO-1, a Personalized Active Immunotherapy, in Patients with Advanced Solid Tumors

crossref（2024）

Cited0Views0Bibtex

Figure 4 from A First-in-Human Phase I Clinical Study with MVX-ONCO-1, a Personalized Active Immunotherapy, in Patients with Advanced Solid Tumors

crossref（2024）

Cited0Views0Bibtex

Table 2 from A First-in-Human Phase I Clinical Study with MVX-ONCO-1, a Personalized Active Immunotherapy, in Patients with Advanced Solid Tumors

crossref（2024）

Cited0Views0Bibtex

Author Statistics

Co-Author

Co-Institution

D-Core

合作者
学生
导师

No result temporarily, you can search similar Scholar with the same research interest

Data Disclaimer

The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn